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Edited by Veli-Pekka LehtoAbstract We previously demonstrated that chronic stimulation
of the b2-adrenergic receptor (b2-AR) increases proliferation of
cultured human cardiac ﬁbroblasts (CF) via an autocrine
mechanism. Here, we investigated the role of endothelin-1 (ET-
1) in this process. ETA-receptor antagonism or protein kinase C
inhibition abolished the b2-AR-induced increase in cell prolifer-
ation. RT-PCR and ELISA analysis demonstrated that although
CF synthesized and secreted ET-1, this occurred independently
of b2-AR stimulation. Furthermore, despite activation of the
MAP kinase pathway, ET-1 treatment did not stimulate CF
proliferation. Therefore, the role of ET-1 in this process is
that of an essential co-factor acting independently of b2-AR
stimulation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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During the development of heart failure (HF), the left ven-
tricle undergoes structural remodeling that serves initially as
an important adaptive response, but is ultimately damaging
[1]. An important contributor to the remodeling process in HF
patients is an increase in myocardial sympathetic nervous ac-
tivity [2]. Indeed, treatment of patients with b-adrenergic re-
ceptor (b-AR) antagonists (b-blockers) reduces adverse
myocardial remodeling with an associated decrease in HF
mortality [3]. A key component of the remodeling process is
the transformation of quiescent cardiac ﬁbroblasts (CF) into a
more responsive myoﬁbroblast phenotype that undergoes in-
creased proliferation, invasion and extracellular matrix turn-
over [4]. In a previous study, we reported that chronic
stimulation of the b2-AR increased the rate of proliferation of
human CF [5]. Hence, a potential mechanism by which b-* Corresponding author. Fax: +44-113-3434-803.
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CM, conditioned medium; ET-1, endothelin-1; ET-R, endothelin
receptor; FCS, fetal calf serum; HF, heart failure; ISO, isoproterenol;
MAPK, mitogen-activated protein kinase; MGM, minimal growth-
promoting medium; PKC, protein kinase C; ppET-1, preproET-1;
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via inhibition of b2-AR-induced CF proliferation. It is there-
fore an important aim to understand the mechanism by which
activation of the b2-AR leads to proliferation of human CF.
Endothelin-1 (ET-1) is a vasoactive peptide that contributes
to the pathophysiology of HF [6]. Indeed, one of the most
accurate markers for clinical outcome in HF patients is plasma
concentrations of big endothelin, the immediate precursor of
ET-1 [7]. Furthermore, animal studies have demonstrated that
ET-1 plays a key role in catecholamine-induced myocardial
remodeling [8,9]. ET-1 exerts its biological actions via two
distinct cell surface receptors, ETA-R and ETB-R, which are
coupled to protein kinase C (PKC) activation through stimu-
lation of phospholipase C [10]. CF express both endothelin
receptor (ET-R) subtypes [11–15] and their activation in rat
CF can stimulate proliferation [16,17] and collagen turnover
[18]. In addition to their ability to respond to ET-1, rat CF can
also synthesize and secrete ET-1 in response to a variety of
stimuli [13,19,20].
Given the ability of CF to both generate and respond to ET-
1, and our prior observation that chronic b2-AR stimulation
enhances human CF proliferation via secretion of autocrine
growth factors [5], we investigated whether ET-1 plays a role in
b2-AR-induced proliferation of human CF.2. Materials and methods
2.1. Reagents
All cell culture reagents were purchased from Invitrogen (Paisley,
UK), except fetal calf serum (FCS) that was from Biowest Ltd
(Ringmer, East Sussex, UK). Isoproterenol (ISO) and human ET-1
were from Sigma (Poole, Dorset, UK). PD142893 and BQ123 were
purchased from Alexis Biochemicals (Nottingham, UK) and BQ788
and GF1093203X were from Calbiochem (Nottingham, UK). All an-
tibodies were from Cell Signaling Technology (Hitchin, Herts., UK).
2.2. Culture of human CF
Biopsies of right atrial appendage were obtained from patients
without left ventricular dysfunction undergoing elective coronary ar-
tery bypass surgery. Local ethical committee approval and written
informed patient consent were obtained. Primary cultures of CF were
harvested, characterized as myoﬁbroblasts, and cultured as described
previously [5,21]. Experiments were performed on passage 2–4 cells
from several patients.
2.3. Proliferation assays
Proliferation assays were performed essentially as described
previously [5]. Brieﬂy, CF were rendered quiescent with serum-free
medium (SFM) for 48 h before exposure to minimal growth-promoting
medium (MGM) containing 2.5% FCS and appropriate supplements.blished by Elsevier B.V. All rights reserved.
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Fig. 1. b2-AR-induced CF proliferation requires ETAR activation. (A)
CF were exposed to MGM alone (open bars) or supplemented with 1
lM ISO (closed bars) for 7 days with or without 10 lM PD142893, 1
lM BQ123 or 1 lM BQ788. Data are expressed as % cell number
observed in MGM control (n ¼ 4). **P < 0:01; *P < 0:05; NS, not
signiﬁcant for the eﬀect of ISO (paired t test). (B) CF were exposed to
C-CM (open bars) or ISO-CM (closed bars) for 7 days with or without
PD142893, BQ123 or BQ788. Data are expressed as % cell number
observed in C-CM control (n ¼ 5). **P < 0:01; NS, not signiﬁcant for
the eﬀect of ISO-CM (paired t test).
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termined after 7 days by counting viable cells using Trypan Blue and a
hemocytometer. Using parallel cultures of CF, we generated control
conditioned medium (C-CM) and ISO-CM as described previously [5].
Both C-CM and ISO-CM were supplemented with 1 lM alprenolol
and 2.5% FCS before use.
2.4. Measurement of ppET-1 mRNA levels
CF were serum-starved for 48 h, then treated with fresh MGM for
24 h before addition of 1 lM ISO for 1–6 h. RNA was extracted and
RT-PCR performed as described previously [5]. PreproET-1 (ppET-1)
forward (50-CAGCGCGGTGGGTGAGAACG-30) and reverse
(50-CAAATGATGTCCAGGTGGCAGAAGTAG-30) primers and
GAPDH primers [5] were synthesized by Invitrogen. ppET-1 (135 bp)
and GAPDH (240 bp) PCR products were resolved by 2% agarose gel
electrophoresis and their relative intensity determined using a Typhoon
9410 Imager and ImageQuant software (Amersham Life Science).
Reactions were optimized for the linear phase of PCR by serial dilu-
tion of RNA to ensure that band intensity was proportional to the
amount of RNA template. Samples were then standardized for equal
expression of GAPDH.
2.5. Measurement of ET-1 secretion
CF were cultured under identical conditions to those in the prolif-
eration assay (Section 2.3). Cell culture supernatants were collected 24
and 48 h after addition of MGM with or without ISO. ET-1 quanti-
ﬁcation was performed using an Endothelin (1–21) immunoassay
(Biomedica, Vienna, Austria) according to the manufacturer’s in-
structions. This assay detects ET-1 and ET-2, but not ET-3 or big
endothelin. The detection limit of the immunoassay was 0.05 fmol/ml.
2.6. Immunoblotting
Serum-starved CF were exposed to ET-1 in SFM for 5 min. Whole
cell homogenates were prepared and immunoblotting performed using
a phospho-speciﬁc p44/42 mitogen-activated protein kinase (MAPK)
antibody or a p44/42 MAPK expression antibody (loading control), as
described previously [22].
2.7. Statistical analysis
All results are expressed as meansSEM with n representing the
number of diﬀerent patients. Diﬀerences between treatment groups
were analyzed using paired t tests. Time course and dose response data
were compared using repeated measures of one-way analysis of vari-
ance (ANOVA) and Newman–Keuls post hoc test. P < 0:05 was
considered statistically signiﬁcant.3. Results
3.1. ETAR activation is essential for b2AR-induced proliferation
of human CF
Human CF cultured in MGM (2.5% FCS) supplemented
with the b-AR agonist ISO (1 lM) underwent a 53.2 3.2%
increase in cell number after 7 days compared with cells grown
in MGM alone (Fig. 1A). This was in agreement with our
previously published report [5] in which we demonstrated that
ISO increased proliferation via activation of the b2-AR. To
investigate whether ET-R activation played a role in this
process, we performed proliferation assays in the presence of a
non-selective ET-R antagonist (PD142893), or selective an-
tagonists for the ETA-R (BQ123) or ETB-R (BQ788). The ISO-
induced increase in CF proliferation was fully inhibited by
PD142893 and BQ123, but not by BQ788 (Fig. 1A), indicating
a role for the ETA-R in the mechanism of b2-AR-induced
proliferation. None of the ET-R antagonists aﬀected the basal
rate of proliferation observed in MGM alone (Fig. 1A).
Our previous work demonstrated that chronic b2-AR stim-
ulation increased proliferation of human CF via increased se-
cretion of autocrine growth factors [5]. Conditioned medium
collected from ﬁbroblasts exposed to MGM containing 1 lMISO (‘‘ISO-CM’’) induced a signiﬁcant increase in proliferation
of parallel cultures of CF compared with control CM from cells
treated with MGM alone (‘‘C-CM’’) [5]. Importantly, ISO-
CM-induced proliferation occurred in the presence of alpren-
olol (a b-AR antagonist), conﬁrming that b2-AR activation is
not required for this second phase of the proliferative eﬀect. In
the present study, we performed proliferation assays using ISO-
CM in the presence of ET-R antagonists to determine whether
ETA-R activation was necessary for the ﬁrst phase of the
proliferative eﬀect (i.e., secretion of autocrine growth factors)
or the second phase (i.e., by acting synergistically with the
autocrine growth factors to increase proliferation). As shown
in Fig. 1B, the ISO-CM-induced increase in cell proliferation
was fully inhibited by PD142893 and BQ123, but not by
BQ788, in agreement with our data in Fig. 1A. None of the
receptor antagonists aﬀected basal proliferation in response to
C-CM (Fig. 1B). These data demonstrate that ETA-R activa-
tion is required for the second phase of the proliferative
response and is independent of b2-AR stimulation.
3.2. Human CF synthesize ppET-1 mRNA and secrete ET-1
independently of b2-AR stimulation
The initial product of the human ET-1 gene is ppET-1, a 212
amino acid peptide that undergoes sequential enzymatic
Fig. 3. ET-1 activates p44/42-MAPK but does not increase CF pro-
liferation. (A) Measurement of p44/42-MAPK activation by immu-
noblotting. CF were exposed to ET-1 for 5 min and homogenates
analysed for phosphorylated p44/42-MAPK (upper panel) or total
p44/42-MAPK expression (lower panel). Bar chart depicts densito-
metric analysis of phospho-MAPK (n ¼ 3). P < 0:01 (ANOVA).
**P < 0:01; *P < 0:05; NS, not signiﬁcant for the eﬀect of ET-1
(Newman–Keuls post-hoc test). (B) Cell proliferation. CF were ex-
posed to MGM supplemented with ET-1 for 7 days. Data are ex-
pressed as % cell number observed in the absence of ET-1 (n ¼ 4–7).
Not statistically signiﬁcant (ANOVA).
Fig. 2. CF synthesize ppET-1 mRNA and secrete ET-1 independently
of b2-AR stimulation. (A) RT-PCR analysis of ppET-1 mRNA levels
following treatment with 1 lM ISO. Bar chart depicts ppET-1/
GAPDH ratio after densitometric analysis (n ¼ 4). P < 0:05 (ANO-
VA). *P < 0:05; NS, not signiﬁcant for the eﬀect of ISO (Newman–
Keuls post-hoc test). (B) Analysis of ET-1 secretion by immunoassay.
CF were exposed to MGM alone (open circles) or MGM supple-
mented with 1 lM ISO (closed circles). NS, not signiﬁcant for the eﬀect
of ISO (paired t test, n ¼ 5).
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synthesized ppET-1 and whether this was modulated by b2-AR
stimulation, we performed semi-quantitative RT-PCR. In cells
exposed to MGM for 24 h, ppET-1 mRNA was readily de-
tectable and levels appeared to decrease slightly over a 6 h
period following addition of ISO (Fig. 2A).
To conﬁrm that CF secreted ET-1 peptide, we exposed cells
to MGM alone or MGM plus 1 lM ISO for 24–48 h and
measured the ET-1 concentration in the medium using an
immunoassay. ET-1 was undetectable (i.e., <0.05 fmol/ml) in
MGM before it was added to the cells. CF cultured in MGM
alone secreted ET-1 with steady-state levels of 1.1 fmol/ml
apparent over the 24–48 h period (Fig. 2B). Supplementation
of MGM with ISO did not aﬀect the level of ET-1 secretion
(Fig. 2B) regardless of the eﬀects observed on ppET-1 mRNA
levels (Fig. 2A).
Taken together, these data demonstrate that human CF
synthesize ppET-1 mRNA and secrete ET-1 independently of
b2-AR activation.
3.3. ET-1 activates p44/42 MAPK but does not induce ﬁbroblast
proliferation
ET-R stimulation is coupled to activation of the p44/42-
MAPK pathway [10]. To conﬁrm that human CF expressedfunctional ET receptors, we therefore investigated whether
exogenously applied ET-1 could stimulate p44/42-MAPK in
these cells. As shown in Fig. 3A, ET-1 induced p44/42
MAPK phosphorylation (activation) in a concentration-
dependent manner, with maximum stimulation induced by 1
lM ET-1.
To investigate whether ET-1 could increase CF prolifera-
tion, we performed proliferation assays in MGM supple-
mented with ET-1. As shown in Fig. 3B, ET-1 did not
stimulate proliferation at any of the concentrations employed.
Therefore, although human CF express functional ET-R
coupled to p44/42 MAPK activation, this does not result in a
proliferative response.
3.4. Role of PKC
As PKC is an important downstream eﬀector of ET-R ac-
tivation, we next investigated whether PKC activation was
involved in the mechanism of ISO-induced CF proliferation.
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Fig. 4. b2-AR-induced CF proliferation requires PKC activation. CF
were exposed to MGM alone (open bars) or MGM supplemented with
1 lM ISO (closed bars) for 7 days with or without 3 lM GF109203X.
Data are expressed as % cell number observed in MGM control
(n ¼ 4). ***P < 0:001; NS, not signiﬁcant for the eﬀect of ISO (paired t
test).
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Fig. 5. Proposed role for ET-1 in the mechanism of b2-AR-induced
proliferation of human CF. (1) ISO stimulates the b2-AR resulting in
increased secretion of autocrine growth factors (GFs) that stimulate
proliferation via activation of speciﬁc growth factor receptors (GF-R).
(2) ET-1 is secreted independently of b2-AR activation and, via acti-
vation of the ETAR and PKC, synergizes with the autocrine growth
factors to increase cell proliferation.
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increase in cell proliferation, without aﬀecting proliferation in
the absence of ISO (Fig. 4), indicating that PKC activation is
essential for b2-AR-induced cell proliferation.4. Discussion
We have previously reported that chronic b2-AR stimulation
increases proliferation of human CF via a mechanism involv-
ing increased secretion of autocrine growth factors [5]. In the
present study we extend these observations and provide evi-
dence for an additional autocrine loop in which ET-1 secre-
tion, ETA-R stimulation and PKC activation play a role.
These two distinct phases of the proliferative response
are summarized in Fig. 5. Although clearly involved in the
ISO-induced proliferative mechanism, ET-1 is not the b2-
AR-induced autocrine factor since (i) ISO treatment does not
increase ET-1 secretion (Fig. 2B) and (ii) ET-1 does not in-
crease CF proliferation (Fig. 3B). Thus, ET-1 is as an essential
cofactor that acts together with the b2-AR-induced autocrine
growth factors to increase CF proliferation. Studies are cur-
rently in progress to identify the autocrine factors which, based
on the evidence presented herein, must synergize with ET-1/
ETA-R to induce a proliferative response.
In the present study, we have established that human CF
synthesize ppET-1 mRNA and secrete ET-1, in agreement
with previous studies using rat CF [13,19,20]. Despite the
expression of functional ET-R coupled to activation of the
p44/42 MAPK pathway, ET-1 did not increase proliferation
of adult human CF under our experimental conditions. Our
ﬁndings clearly diﬀer from those in neonatal and adult rat
[16,17] and embryonic human [23] CF in which ET-1 elicited
a proliferative response, and may highlight important inter-
species or developmental diﬀerences. In our previous study
using human CF [5] we also demonstrated that forskolin, an
activator of adenylyl cyclase, was unable to induce cell pro-
liferation despite mimicking the eﬀects of ISO on p44/42
MAPK activation. These ﬁndings, together with our presentdata obtained with ET-1, suggest that although p44/42
MAPK activation may be necessary for inducing human CF
proliferation [24], its activation alone is insuﬃcient to elicit a
proliferative response.
In the normal human left ventricle the ETA-R accounts for
60%, and the ETB-R 40%, of total ET-R expression [25]. At
the cellular level, ETA-R mRNA expression is localized to
myocytes and non-myocytes (predominantly ﬁbroblasts),
whereas ETB-R mRNA is detected almost exclusively in non-
myocytes [14]. Combined expression of ETA-R and ETB-R has
been reported in cultured rat and embryonic human CF [11–
13,15], and the ETB-R may account for as much as 75% of ET-
R expression in adult rat CF [11]. It is therefore likely that the
cells used in our present study expressed both the ETA-R and
ETB-R. Although this was not directly investigated, the func-
tional eﬀects of ET-1 in the present study were mediated via
the ETA-R.
A number of animal studies have determined that cate-
cholamine-induced cardiac hypertrophy can be signiﬁcantly
reduced by oral administration of non-selective ETA=B [8] or
selective ETA [9] receptor antagonists. Hence, it was surprising
that transgenic mice with cardiomyocyte-speciﬁc knockout of
the ETA-R were recently reported to show no reduction in
ISO-induced cardiac hypertrophy compared with control mice
[26]. However, one explanation oﬀered for this disparity was
that the requirement for ETA-R activation in ISO-induced
myocardial remodeling may be at the level of the CF rather
than the cardiomyocyte, as ETAR levels in non-myocytes are
not reduced in this model [26]. Our demonstration that the
ISO-induced increase in CF proliferation requires ETAR ac-
tivation provides corroborative evidence that this may indeed
be the case.
In summary, we report here that ET-1, acting via the ETA-R
and PKC activation, is an essential co-factor for b2-AR-induced
proliferation of human CF. These ﬁndings provide important
new insights into the relationship between the adrenergic and
endothelin systems at the level of the CF, and may have
implications for the control of adverse myocardial remodeling
in man.
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